Table 2C.

Comparison of prevalence of biomarkers identified in cfDNA and tissue as compared with The Cancer Genome Atlas

cfDNATissue
Guideline-recommended biomarkersTCGAPercent of total cohortFrequency of alteration (%) in those with completed testing for biomarker of interestPercent of total cohortFrequency of alteration (%) in those with completed testing for biomarker of interest
EGFR mutation11.3%15.2%16.0%14.2%17.3%
ALK fusion1.3%2.1%2.2%3.2%4.0%
ROS1 fusion1.7%0.0%0.0%0.7%1.2%
BRAF mutation (V600E)7.0%0.7%0.7%0.7%2.1%
RET fusion0.9%1.1%1.1%0.0%0.0%
ERBB2 mutation1.7%1.1%1.1%0.4%1.6%
MET exon 14 skipping variant4.3%3.5%3.7%1.8%7.5%
MET amplification2.2%5.3%5.6%0.4%1.6%
MET focal amplification1.8%1.9%
MET aneuploidy3.5%3.7%
KRAS mutation32.2%31.6%33.2%8.5%32.9%
  • NOTE: Biomarker frequency was calculated across the entire cohort (N = 282) and for those that had complete testing (positive or negative) for the biomarker of interest, 268 for cfDNA and for tissue see Table 3 and Supplementary Table S2.